[go: up one dir, main page]

AU727448B2 - Nutritional composition for subjects under stress - Google Patents

Nutritional composition for subjects under stress Download PDF

Info

Publication number
AU727448B2
AU727448B2 AU79277/98A AU7927798A AU727448B2 AU 727448 B2 AU727448 B2 AU 727448B2 AU 79277/98 A AU79277/98 A AU 79277/98A AU 7927798 A AU7927798 A AU 7927798A AU 727448 B2 AU727448 B2 AU 727448B2
Authority
AU
Australia
Prior art keywords
composition
carnitine
stress
alkanoyl
ginseng
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU79277/98A
Other versions
AU7927798A (en
Inventor
Claudio Cavazza
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sigma Tau Industrie Farmaceutiche Riunite SpA
Original Assignee
Sigma Tau Industrie Farmaceutiche Riunite SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Industrie Farmaceutiche Riunite SpA filed Critical Sigma Tau Industrie Farmaceutiche Riunite SpA
Publication of AU7927798A publication Critical patent/AU7927798A/en
Application granted granted Critical
Publication of AU727448B2 publication Critical patent/AU727448B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17Amino acids, peptides or proteins
    • A23L33/18Peptides; Protein hydrolysates
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15Vitamins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Description

-I-
WO 99/03364 PCTIIB98/0I 056 NUTRITONAL COMPOSITON FOR SUBJECTS UNDER STRESS
DESCRIPTION
The present invention relates to a nutritional composition or medical food for subjects in a debilitated state as a result of stress.
In the developed countries, stress syndrome afflicts a substantial number of people. The causes of the stress are multiple and attributable mainly to living conditions in large and overcrowded urban areas and to the problems these give rise to such as traffic, noise and pollution. Another imtportant cause consists in problems associated with working activity or economic worries.
This syndrome afflicts all social classes, but mainly affects is people involved in the production cycle, who often, as a result, are subject to greater competitive stress stimuli both in the work environment and in the conduct of their social relations.
Generally speaking, stress syndrome is not a debilitating "disease" to the extent that it makes people bed-ridden, but it is certainly a frequent cause of people taking days off work. Since it afflicts a substantial number of individuals, it causes a considerable burden of economic damage to the entire community during the working year. Stress syndrome, which in the past was improperly called "nervous breakdown", is characterised, in the absence of active disease, by concomitant states of malaise, such as a lack of strength, debilitation, states of mental and physical fatigue, lack of concentration and attention, and lack of sexual vigour and libido.
There are no specific drugs for the treatment of stress.
Temporary detachment from the causes of the stress, for instance by spending a holiday in a pleasant locality and in a relaxing WO 99/03364 WO 9903364PCTJIB98/0I 056 2 environment, would certainly have a positive effect, facilitating recovery of mental and physical well-being with an improvement in physical performance and an increase in sexual vigour and libido.
This, however, is not always possible for various reasons such as, for example, work commitments, family demands and economic difficulties.
A number of patients suffering from stress are treated with benzodiazepines or with drugs which are active in mood disorders.
Benzodiazepines are used to alleviate symptoms such as anxiety or irritability, but present the drawback of causing addiction as well as further depressing libido and sexual vigour, thus triggering a mechanism in male subjects of reproductive age which itself proves to be a cause of additional malaise.
A number of substances which axe useful for the treatment of is sexual. impotence of psychogenic or other origin are already well known. Equally well known are substances endowed with stimulant activity. For example, L-carnitine, when used for the treatment of patients undergoing regular dialysis treatment, also induces recovery of normal sexual function in such patients (De Felice SL, Lyons P, Gaffar MC, Sheridan MJ, Dial-Transplant, 1996., vol/las/pg.
25/6 368-373).
Popular medicine (and belief) in oriental and South American countries (China, Brazil) have, since time immemorial, accredited the extracts of the roots, bark and leaves of various "exotic" plants with multiple therapeutic and stimulant effects. Ginseng has been used in Chinese medicine for more than 2000 years for the treatment of sexual impotence and for other diseases. Also well knlown is the activity of yohimbine in improving sexual function; see, for example, "Clinical Studies in Impotence": K Reid et al., Lancet 2, 3o 421-423 (1987). Guai-ana. is used by Brazilian indigenous WO 99/03364 PCT/IB98/01056 3 populations for the preparation of a stimulating beverage (Pharmacognosy, Edward P Claus, Varro E Tyler, Lynn R Brady, 6th edition pp. 292-293). Damiana has also long been known to be endowed, according to popular belief, with stimulant activity (J s Psychoactive Drugs 16 267-268, 1984).
The purpose of the present invention is now to provide a therapeutic medical food suitable for alleviating and treating states of malaise caused by stress and for promoting sexual vigour. The therapeutic medical food of the invention comprises the following compounds in combination: 1) L-carnitine or an alkanoyl L-carnitine in which the linear or branched-chain alkanoyl has 2-8, and preferably 2-6, carbon atoms, or one of their pharnacologically acceptable salts; 2) ginseng (natural extract of Panax ginseng); 3) yohimbine (natural extract of Corynanthe yohimbe); 4) guarana (natural extract of Paullinia cupana); damiana (natural extract of Tumera diffusa, var. aphrodisiaco4; 6) lecithin of soya, and 7) malic acid.
The alkanoyl L-carnitine should preferably be chosen from among the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its pharmacologically acceptable salts.
What is meant by pharmacologically acceptable salt of L- S 25 carnitine or of an alkanoyl L-carnitine is any salt of these with an acid which does not give rise to unwanted toxic or side effects. Such acids are well known' to pharmacologists and experts in pharmacy.
Non-limiting examples of pharmacologically acceptable salts of L-carnitine or of the alkanoyl L-carnitines are chloride, bromide, orotate, acid aspartate, acid citrate, acid phosphate, fumarate and WO 99/03364 PCT/IB98/01056 4 acid fumarate, lactate, maleate and acid maleate, acid oxalate, acid sulphate, glucose phosphate, tartrate and acid tartrate.
The components of the combination according to the invention, once combined, exhibit an unexpected potent synergistic effect s which brings about an improvement in physical performance and in the mental and physical condition of patients suffering from stress syndrome. Very important and surprising is the synergistic effect shown by the combination of ginseng, yohimbine and L-carnitine in restoring sexual vigour and libido.
The effect of the combination is, in fact, distinctly superior to the sum of the effects of the individual components.
Of particular interest is the interaction between malic acid and L-carnitine. The complementary effect exerted by these two compounds on energy production via two different metabolic pathways malic acid via the Krebs cycle, and L-carnitine via 3oxidation stimulates the body to produce a large amount of energy, which is useful in enabling the individual to emerge from the state of fatigue, debilitation or asthenia caused by stress.
The interaction between guarana and damiana also results in an intense stimulatory effect, enabling most subjects presenting a state of torpor or lack of interest to emerge from these conditions.
L-carnitine and lecithin of soya favour the metabolisation of fatty acids, exerting a hypolipaemic effect on the body, which, though having no direct repercussions in terms of improving stress syndrome, is aimed at enhancing the individual's general state of health.
The weight-to-weight ratio of L-carnitine or of an alkanoyl Lcarnitine to ginseng, yohimbine, guarana and damiana may vary over a broad range, This ratio should preferably range from WO 99/03364 PCT/IB98/01056 1:0.1:0.0025:0.1;0.1 to 1:10:0.25:100:100. One preferred ratio is 1:1,0.025:1:1.
By way of non-limiting examples a number of sachet formulations according to the invention are given containing the s following components in combination: Com-Position I L-carnitine HC1 200 mg Ginseng 200 mig Lecithin of soya 400 mig Aspartame 20 mig Sucrose 1500 mg Tangerine flavouring 100 Mig Yohimbine 5 Mg Malic acid 50 Mg Granular mannitol q. a. to 3000 mg Composition 2 L-carnitine HM 200 mg Ginseng 200 mg Lecithin of soya 200 mig 2o Aspartame 20 mg Sucrose 1000 nig Tangerine flavouring 100. mg Yahimbine 5 Mg Guarana 200 mg Damniana 200 mg Malic acid 50 Mg Granular mannitol q.s. to 3000 mg WO 99/03364 WO 9903364PCT/IB98/01 056 6 Composition 3 L-carnitine HCl 200 mg Ginseng 200 mg Lecithin of soya 200 mg s Asp artamne 20 mg Sucrose 1000 mg Tangerine flavouring 100 mg Yohirnbine 5 mg Guarana 500 mg io Damiana 500 Mg Malic acid 50 Mng Granular mannitol q.s. to 3000 mg The composition according to the invention may additionally contain vitamins, metals, coenzymes, inorganic or organic is antioxidants or their precursors.

Claims (8)

1. A medical food composition suitable for alleviating and treating states of malaise caused by stress, comprising the following in combination: .L-carnitine or an alkanoyl L-carnitine in which the linear or branched-chain alkanoyl group has 2-8, and preferably 2-6 carbon atoms, or one of their pharmacologically acceptable salts; a mixture of natural plant extracts; lecithin of soya; malic acid.
2. The composition of claim 1, wherein the alkanoyl L-carnitine is selected from the group comprising acetyl, propionyl, butyryl, valeryl and isovaleryl L-carnitine or one of its is pharmacologically acceptable salts.
3. The composition of claim 1, wherein the natural plant extracts are selected from the group comprising the natural extract of Corynanthe yohimbe or yohimbine, the natural extract of Panax ginseng or ginseng, the natural extract of Paullinia cupana or guarana, and the natural extract of Tumera diffusa or damiana.
4. The composition of claim 3, wherein the weight-to-weight ratio of L-carnitine or of an alkanoyl L-carnitine to ginseng, yohimbine, guarana and damiana ranges from 1:0.1:0.0025:0.1:0.1 to 1;10:0.25:100:100. The composition of claim 4, wherein said ratio is 1:1:0.025; 1:1.
6. The composition of the preceding claims, further comprising vitamins, metals, coenzymes, inorganic or organic antioxidants or their precursors. WO 99/03364 PCT/IB98/01056 8
7. The composition of any of the preceding claims for the treatment of stress-induced or psychogenic sexual impotence.
8. The composition of any of the preceding claims for the treatment of states of fatigue, lack of strength or asthenia caused by stress.
9. The composition of any of the preceding claims, which presents itself in the form of a solid, semisolid, liquid, semiliquid, powder, grains, tablets, capsules, granules, or powder for oral use.
AU79277/98A 1997-07-16 1998-07-10 Nutritional composition for subjects under stress Ceased AU727448B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ITRM97A000435 1997-07-16
IT97RM000435A IT1293539B1 (en) 1997-07-16 1997-07-16 NUTRITIONAL COMPOSITION FOR SUBJECTS IN A STATE OF DEBILITATION CAUSED BY STRESS
PCT/IB1998/001056 WO1999003364A1 (en) 1997-07-16 1998-07-10 Nutritional composition for subjects under stress

Publications (2)

Publication Number Publication Date
AU7927798A AU7927798A (en) 1999-02-10
AU727448B2 true AU727448B2 (en) 2000-12-14

Family

ID=11405180

Family Applications (1)

Application Number Title Priority Date Filing Date
AU79277/98A Ceased AU727448B2 (en) 1997-07-16 1998-07-10 Nutritional composition for subjects under stress

Country Status (11)

Country Link
EP (1) EP0999757A1 (en)
JP (1) JP2001510026A (en)
KR (1) KR20010021694A (en)
CN (1) CN1263439A (en)
AU (1) AU727448B2 (en)
CA (1) CA2296540A1 (en)
HU (1) HUP0004526A3 (en)
IT (1) IT1293539B1 (en)
PL (1) PL338079A1 (en)
SK (1) SK181999A3 (en)
WO (1) WO1999003364A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT410277B (en) * 2001-02-22 2003-03-25 Peter Dr Frigo DRINK
LV12978B (en) * 2001-09-07 2003-05-20 Ivars Kalvins Pharmaceutical composition
ITRM20010708A1 (en) * 2001-12-04 2003-06-04 Sigma Tau Ind Farmaceuti USE OF AN ALCANOIL L-CARNITINE FOR THE TREATMENT OF ERECTILE DYSFUNCTION.
WO2004028550A2 (en) * 2002-09-28 2004-04-08 Boehringer Ingelheim International Gmbh Composition comprising panax ginseng and paullinia cupana extracts
DE102005053241A1 (en) * 2005-11-08 2007-05-16 Schwabe Willmar Gmbh & Co Extracts of the bark of Corynanthe species and their use, as well as pharmaceuticals containing them, dietetic foods and pharmaceutical preparations
WO2009066712A1 (en) * 2007-11-21 2009-05-28 Kracie Pharma, Ltd. Aromatase inhibitor
JP6446265B2 (en) * 2014-12-26 2018-12-26 花王株式会社 Solid composition
CN113116898A (en) * 2021-04-20 2021-07-16 北京天玺宝科技有限公司 Composition containing levocarnitine or acetyl levocarnitine and yohimbine with weight losing function and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
WO1997042928A1 (en) * 1996-05-14 1997-11-20 Lvmh Recherche Topical slimming composition
US5744187A (en) * 1996-12-16 1998-04-28 Gaynor; Mitchel L. Nutritional powder composition

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5626849A (en) * 1995-06-07 1997-05-06 Reliv International, Inc. Weight loss composition for burning and reducing synthesis of fats
WO1997042928A1 (en) * 1996-05-14 1997-11-20 Lvmh Recherche Topical slimming composition
US5744187A (en) * 1996-12-16 1998-04-28 Gaynor; Mitchel L. Nutritional powder composition

Also Published As

Publication number Publication date
IT1293539B1 (en) 1999-03-01
EP0999757A1 (en) 2000-05-17
AU7927798A (en) 1999-02-10
CN1263439A (en) 2000-08-16
ITRM970435A1 (en) 1999-01-16
PL338079A1 (en) 2000-09-25
HUP0004526A2 (en) 2001-04-28
SK181999A3 (en) 2000-10-09
WO1999003364A1 (en) 1999-01-28
CA2296540A1 (en) 1999-01-28
ITRM970435A0 (en) 1997-07-16
JP2001510026A (en) 2001-07-31
KR20010021694A (en) 2001-03-15
HUP0004526A3 (en) 2001-11-28

Similar Documents

Publication Publication Date Title
JP4166951B2 (en) A combination of carnitine and resveratrol for the prevention or treatment of cerebral and age-related diseases
GB2596849A (en) Nutritional supplement composition for treating coronavirus infections, cancer, ME, post viral & Chronic fatigue syndrome & neurodegeneration in an individual
CN1625406A (en) Preparations containing lysophosphatidylserine for the prevention and treatment of stressful states in warm-blooded animals
US7674482B2 (en) Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US20090011048A1 (en) Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
KR102539374B1 (en) Compositions for enhancing brain activity
KR100481188B1 (en) Use of Alkanoyl-L-Carnitine for the Treatment of Glutamate-Related Diseases
AU727448B2 (en) Nutritional composition for subjects under stress
US5482712A (en) Galenic composition
KR100711276B1 (en) Utilization of phosphatidylserine in the treatment of attention deficit syndrome ADHS
US20040213829A1 (en) Dietary supplement
JP2007500755A (en) How to reduce symptoms of premenstrual syndrome
US20030194453A1 (en) Dietary supplement
JP2007077080A (en) Composition for preventing or treating fatigue or malaise
MXPA00000442A (en) Nutritional composition for subjects under stress
DE60109651T2 (en) CARNITINE AND HUPERZINE COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF HYPERACTIVITY WITH ATTENTION DISORDERS IN CHILDREN
CZ200088A3 (en) Nutrition preparation for stress subjects
JP2009541308A (en) Means and methods for human vigor
HUP0202079A2 (en) Cardioactive composition comprising l-carnitine and its derivatives and crataegus extracts
Thier Acute and chronic alcohol-related disorders
JP2008019190A (en) Natural product-derived motivation improver
KR20230106783A (en) Composition for improving male sexual function containing mixture extract using supercritical fluid extraction method as an active ingredient
MXPA01003569A (en) Combination of carnitines and resveratrol for prevention or treatment of cerebral and ageing disorders
WO2008152624A2 (en) Herbal energy-enhancing formulation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired